The long-term treatment of life-threatening pica: A case study of a woman with profound mental retardation living in an applied setting

1995 ◽  
Vol 7 (1) ◽  
pp. 39-50 ◽  
Author(s):  
Lynn C. Bogart ◽  
Wayne C. Piersel ◽  
Edward J. Gross
Keyword(s):  
Mental Retardation ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Life Threatening ◽  
Profound Mental Retardation

Long-Term Treatment of Severe Dysarthria

1988 ◽  
Vol 53 (4) ◽  
pp. 433-440 ◽  
Author(s):  
Marianne B. Simpson ◽  
James A. Till ◽  
Anne M. Goff
Keyword(s):  
Speech Intelligibility ◽  
Measurement Techniques ◽  
Term Treatment ◽  
Single Subject ◽  
Basilar Artery Thrombosis ◽  
Long Term Treatment ◽  
Velopharyngeal Function

This case study describes the long-term treatment and changing symptoms in a single subject with dysarthria secondary to basilar artery thrombosis. Initially, the subject was anarthric. Treatment efforts thereafter were directed toward modifying speech respiration, velopharyngeal function, articulatory precision, speech intensity, and speech intelligibility. A variety of treatment and measurement techniques are illustrated. The behavioral change resulting from each of the treatments was small. However, when combined, these small gains in conjunction with some neurological recovery resulted in significantly improved communication and quality of life for this subject. Implications for management Of similar subjects are discussed.

Sumatriptan dose increase-induced acute angle closure glaucoma in chronic migraine sufferer

2021 ◽  
Vol 14 (2) ◽  
pp. e235880
Author(s):  
Sokratis Zormpas ◽  
Artemis Matsou ◽  
Diandra Monique Antunes ◽  
Chris Panos
Keyword(s):  
Term Treatment ◽  
Acute Angle ◽  
Angle Closure ◽  
Dose Increase ◽  
Drug Induced ◽  
Long Term Treatment ◽  
Acute Angle Closure ◽  
Acute Angle Closure Glaucoma

In this case study, we explore a case of bilateral acute angle closure (AAC) attack detected in a 52-year-old female patient with no other ophthalmic background or predisposition to angle closure, following an increase of her regular sumatriptan dose used for migraine relief. Even though the initial presentation was misinterpreted as migraine attack, it nevertheless alerted the treating physicians to immediate cessation of the drug, allowing for the pertinent ocular symptomatology to be unveiled. Drug-induced bilateral AAC is a rare occurrence and can lead to significant ocular morbidity if not detected and treated early. Clinicians of emergency care should be aware of this uncommon association, as prompt ophthalmology input is vital. Interestingly, although it would be anticipated that people prone to angle closure attack after sumatriptan intake would exhibit symptoms after initiation of the drug, our patient suffered an attack while on long-term treatment and following dose increase.

scholarly journals Methotrexate induced ventricular arrhythmia as a medication error: a case report

2019 ◽  
Vol 8 (9) ◽  
pp. 2163
Author(s):  
Shailja S. Shah ◽  
Sapna Gupta ◽  
Jasvin Vala ◽  
Supriya D. Malhotra ◽  
Pankaj Patel
Keyword(s):  
Ventricular Arrhythmia ◽  
Therapeutic Index ◽  
Term Treatment ◽  
Weekly Dose ◽  
Narrow Therapeutic Index ◽  
Patient Comprehension ◽  
Long Term Treatment ◽  
Daily Dose ◽  
Life Threatening

Methotrexate (MTX) is the most widely used drug in clinical practice for long term treatment of connective tissue disorders. As this drug has narrow therapeutic index, if it goes unmonitored can lead to life threatening complications. Herein we are describing the case of a patient who presented with ventricular arrhythmia, due to failure to execute MTX therapy in the prescribed frequency and took daily dose of MTX which was meant to be taken as a weekly dose pointing to failure of patient education or patient comprehension regarding MTX and finally succumbed due to cardiogenic shock. We concluded this causality as probable/likely category according to WHO-UMC causality categories. 

Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura

Blood ◽  
2002 ◽  
Vol 99 (4) ◽  
pp. 1482-1485 ◽  
Author(s):  
Giovanni Emilia ◽  
Monica Morselli ◽  
Mario Luppi ◽  
Giuseppe Longo ◽  
Roberto Marasca ◽  
...  
Keyword(s):  
Cyclosporin A ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Complete Response ◽  
Term Treatment ◽  
Thrombocytopenic Purpura ◽  
Long Term Treatment ◽  
Life Threatening ◽  
Difficult Challenge

Treatment of severe, chronic idiopathic thrombocytopenic purpura (ITP) refractory to most usual therapies is a difficult challenge. Little information exists on the clinical use of cyclosporin A (CyA) in the treatment of ITP. This report describes long-term treatment with CyA (median, 40 months) and follow-up (median, 36.8 months) in 12 adult patients with resistant ITP. CyA used in relatively low doses (2.5-3 mg/kg of body weight per day) led to a clinical improvement in 10 patients (83.3%). Five had a complete response (41.1%), 4 a complete response to maintenance therapy (33.3%), and one a partial response (8.3%). Two patients had no response. Most patients with a response (60%) had a long-term remission (mean, 28.6 months) after discontinuation of CyA. One patient had a relapse of ITP 4 years after CyA therapy was stopped. Side effects were moderate and transient, even in patients dependent on continued CyA treatment. CyA seems to represent reasonable salvage treatment in severe, potentially life-threatening, refractory ITP.

Sign in / Sign up

Export Citation Format

Share Document